|
1
|
Baron BW, Anastasi J, Thirman MJ, Furukawa
Y, Fears S, Kim DC, Simone F, Birkenbach M, Montag A, Sadhu A, et
al: The human programmed cell death-2 (PDCD2) gene is a target of
BCL6 repression: Implications for a role of BCL6 in the
down-regulation of apoptosis. Proc Natl Acad Sci USA. 99:2860–2865.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vaux DL and Häcker G: Cloning of mouse
RP-8 cDNA and its expression during apoptosis of lymphoid and
myeloid cells. DNA Cell Biol. 14:189–193. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang Y, Jin Y and Du W: Programmed cell
death 2 functions as a tumor suppressor in osteosarcoma. Int J Clin
Exp Pathol. 8:10894–10900. 2015.PubMed/NCBI
|
|
4
|
Zhang J, Wei W, Jin HC, Ying RC, Zhu AK
and Zhang FJ: Programmed cell death 2 protein induces gastric
cancer cell growth arrest at the early S phase of the cell cycle
and apoptosis in a p53-dependent manner. Oncol Rep. 33:103–110.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang W, Song XW, Bu XM, Zhang N and Zhao
CH: PDCD2 and NCoR1 as putative tumor suppressors in gastric
gastrointestinal stromal tumors. Cell Oncol (Dordr). 39:129–137.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barboza N, Minakhina S, Medina DJ, Balsara
B, Greenwood S, Huzzy L, Rabson AB, Steward R and Schaar DG: PDCD2
functions in cancer cell proliferation and predicts relapsed
leukemia. Cancer Biol Ther. 14:546–555. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kars MD, Iseri OD and Gündüz U: A
microarray based expression profiling of paclitaxel and vincristine
resistant MCF-7 cells. Eur J Pharmacol. 657:4–9. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rani B, Malfettone A, Dituri F, Soukupova
J, Lupo L, Mancarella S, Fabregat I and Giannelli G: Galunisertib
suppresses the staminal phenotype in hepatocellular carcinoma by
modulating CD44 expression. Cell Death Dis. 9:3732018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mir N, Jayachandran A, Dhungel B, Shrestha
R and Steel JC: Epithelial-to-mesenchymal transition: A mediator of
sorafenib resistance in advanced hepatocellular carcinoma. Curr
Cancer Drug Targets. 17:698–706. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miyazaki H, Takahashi RU, Prieto-Vila M,
Kawamura Y, Kondo S, Shirota T and Ochiya T: CD44 exerts a
functional role during EMT induction in cisplatin-resistant head
and neck cancer cells. Oncotarget. 9:10029–10041. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park JH, Shin JE and Park HW: The role of
hippo pathway in cancer stem cell biology. Mol Cells. 41:83–92.
2018.PubMed/NCBI
|
|
13
|
El-Khoueiry AB, O'Donnell R, Semrad TJ,
Mack P, Blanchard S, Bahary N, Jiang Y, Yen Y, Wright J, Chen H, et
al: A phase I trial of escalating doses of cixutumumab (IMC-A12)
and sorafenib in the treatment of advanced hepatocellular
carcinoma. Cancer Chemother Pharmacol. 81:957–963. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang K, Chen J, Zhou H, Chen Y, Zhi Y,
Zhang B, Chen L, Chu X, Wang R and Zhang C: PU.1/microRNA-142-3p
targets ATG5/ATG16L1 to inactivate autophagy and sensitize
hepatocellular carcinoma cells to sorafenib. Cell Death Dis.
9:3122018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nagai T, Arao T, Furuta K, Sakai K, Kudo
K, Kaneda H, Tamura D, Aomatsu K, Kimura H, Fujita Y, et al:
Sorafenib inhibits the hepatocyte growth factor-mediated epithelial
mesenchymal transition in hepatocellular carcinoma. Mol Cancer
Ther. 10:169–177. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dong J, Zhai B, Sun W, Hu F, Cheng H and
Xu J: Activation of phosphatidylinositol 3-kinase/AKT/snail
signaling pathway contributes to epithelial-mesenchymal
transition-induced multi-drug resistance to sorafenib in
hepatocellular carcinoma cells. PLoS One. 12:e01850882017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
van Malenstein H, Dekervel J, Verslype C,
Van Cutsem E, Windmolders P, Nevens F and van Pelt J: Long-term
exposure to sorafenib of liver cancer cells induces resistance with
epithelial-to-mesenchymal transition, increased invasion and risk
of rebound growth. Cancer Lett. 329:74–83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao P, Wang S, Jiang J, Liu H, Zhu X,
Zhao N, Li J, Yin Y, Pan X, Yang X, et al: TIPE2 sensitizes
osteosarcoma cells to cis-platin by down-regulating MDR1 via the
TAK1-NF-κB and -AP-1 pathways. Mol Immunol. 101:471–478. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marra M, Sordelli IM, Lombardi A, Lamberti
M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R,
Accardo M, et al: Molecular targets and oxidative stress biomarkers
in hepatocellular carcinoma: An overview. J Transl Med. 9:1712011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao P, Li M, Wang Y, Chen Y, He C, Zhang
X, Yang T, Lu Y, You J, Lee RJ and Xiang G: Enhancing anti-tumor
efficiency in hepatocellular carcinoma through the autophagy
inhibition by miR-375/sorafenib in lipid-coated calcium carbonate
nanoparticles. Acta Biomater. 72:248–255. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Caraglia M, Giuberti G, Marra M, Addeo R,
Montella L, Murolo M, Sperlongano P, Vincenzi B, Naviglio S, Prete
SD, et al: Oxidative stress and ERK1/2 phosphorylation as
predictors of outcome in hepatocellular carcinoma patients treated
with sorafenib plus octreotide LAR. Cell Death Dis. 2:e1502011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen J, Jin R, Zhao J, Liu J, Ying H, Yan
H, Zhou S, Liang Y, Huang D, Liang X, et al: Potential molecular,
cellular and microenvironmental mechanism of sorafenib resistance
in hepatocellular carcinoma. Cancer Lett. 367:1–11. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shibue T and Weinberg RA: EMT, CSCs, and
drug resistance: The mechanistic link and clinical implications.
Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Otsuki Y, Saya H and Arima Y: Prospects
for new lung cancer treatments that target EMT signaling. Dev Dyn.
247:462–472. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou L, Lv X, Yang J, Zhu Y, Wang Z and Xu
T: Overexpression of Napsin A resensitizes drug-resistant lung
cancer A549 cells to gefitinib by inhibiting EMT. Oncol Lett.
16:2533–2538. 2018.PubMed/NCBI
|
|
26
|
Yin X, Zhang BH, Zheng SS, Gao DM, Qiu SJ,
Wu WZ and Ren ZG: Coexpression of gene Oct4 and Nanog initiates
stem cell characteristics in hepatocellular carcinoma and promotes
epithelial-mesenchymal transition through activation of Stat3/Snail
signaling. J Hematol Oncol. 8:232015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zheng HC: The molecular mechanisms of
chemoresistance in cancers. Oncotarget. 8:59950–59964.
2017.PubMed/NCBI
|
|
28
|
Teicher BA: Acute and chronic in vivo
therapeutic resistance. Biochem Pharmacol. 77:1665–1673. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
van Zijl F, Zulehner G, Petz M, Schneller
D, Kornauth C, Hau M, Machat G, Grubinger M, Huber H and Mikulits
W: Epithelial-mesenchymal transition in hepatocellular carcinoma.
Future Oncol. 5:1169–1179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang H, Mizumachi T, Carcel-Trullols J,
Li L, Naito A, Spencer HJ, Spring PM, Smoller BR, Watson AJ,
Margison GP, et al: Targeting human 8-oxoguanine DNA glycosylase
(hOGG1) to mitochondria enhances cisplatin cytotoxicity in hepatoma
cells. Carcinogenesis. 28:1629–1637. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wen L, Liang C, Chen E, Chen W, Liang F,
Zhi X, Wei T, Xue F, Li G, Yang Q, et al: Regulation of Multi-drug
Resistance in hepatocellular carcinoma cells is TRPC6/Calcium
dependent. Sci Rep. 6:232692016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jiao M and Nan KJ: Activation of PI3
kinase/Akt/HIF-1α pathway contributes to hypoxia-induced
epithelial-mesenchymal transition and chemoresistance in
hepatocellular carcinoma. Int J Oncol. 40:461–468. 2012.PubMed/NCBI
|
|
33
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: An alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen JS, Li HS, Huang JQ, Zhang LJ, Chen
XL, Wang Q, Lei J, Feng JT, Liu Q and Huang XH: Down-regulation of
Gli-1 inhibits hepatocellular carcinoma cell migration and
invasion. Mol Cell Biochem. 393:283–291. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zucchini-Pascal N, Peyre L and Rahmani R:
Crosstalk between beta-catenin and snail in the induction of
epithelial to mesenchymal transition in hepatocarcinoma: Role of
the ERK1/2 pathway. Int J Mol Sci. 14:20768–20792. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li W, Liu C, Tang Y, Li H, Zhou F and Lv
S: Overexpression of Snail accelerates adriamycin induction of
multidrug resistance in breast cancer cells. Asian Pac J Cancer
Prev. 12:2575–2580. 2011.PubMed/NCBI
|
